Drug Development
A Rational Approach to the Development of Drug Combinations in Thoracic Oncology
D. Ross Camidge, MD, PhD
H&O What is the typical approach to the development of drug combinations in oncology? DRC In clinical trials, drug combinations can reflect several scenarios. A trial […]
In This Issue
Ovarian Cancer
Management of Rare Epithelial Ovarian Cancers
David M. Gershenson, MD
Gene Sequencing
Next-Generation Sequencing for the General Cancer Patient
Monica Avila, MD, and Funda Meric-Bernstam, MD
Prostate Cancer
Imaging of Prostate Cancer With Positron Emission Tomography
Michael E. Zimmerman, Alexa R. Meyer, MD, Steven P. Rowe, MD, PhD, and Michael A. Gorin, MD
Breast Cancer
Highlights in Breast Cancer From the 2019 American Society of Clinical Oncology Annual Meeting
Colorectal Cancer
When to Use Triplet Chemotherapy as First-Line Treatment in Metastatic Colorectal Cancer
Chiara Cremolini, MD, PhD
From Recent Issues
Myeloma
Insights Into the Management of Older Patients With Multiple Myeloma
H&O What is the age distribution among patients with multiple myeloma? KA Studies have shown that the median age of patients with multiple myeloma is […]
Venous Thromboembolism
Risk Factors for and Clinical Management of Venous Thromboembolism During Pregnancy
Abstract: Venous thromboembolism (VTE), which comprises deep vein thrombosis and pulmonary embolism, is one of the leading causes of non-obstetric maternal death in the United […]
Hematology
Diagnosis and Treatment of Hemophilia
Abstract: Hemophilia A and B are inherited bleeding disorders characterized by deficiency or dysfunction of coagulation protein factors VIII and IX, respectively. Recurrent joint and […]
Supplements
lymphoma
Advances in Aggressive Lymphoma From the 2019 American Society of Clinical Oncology Annual Meeting
A Review of Selected Presentations From the 2019 ASCO Annual Meeting • May 31-June 4, 2019 • Chicago, Illinois Rituximab Maintenance for Patients With Diffuse […]
Colorectal cancer
The Mechanism of Action of Regorafenib in Colorectal Cancer: A Guide for the Community Physician
Abstract: In 2012, the US Food and Drug Administration approved the kinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer who have been previously […]
CLL
Highlights in Chronic Lymphocytic Leukemia From the 2019 American Society of Clinical Oncology Annual Meeting
A Review of Selected Presentations From the 2019 ASCO Annual Meeting • May 31-June 4, 2019 • Chicago, Illinois Final Analysis From RESONATE: Six-Year Follow-Up in […]
Lymphoma
Surveillance Scanning in Lymphoma
Abstract: Although the role of imaging in the management of most lymphomas is well established at baseline, during treatment, and following treatment, surveillance imaging after […]
Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma: Review of Current Evidence and Future Directions
Abstract: Mantle cell lymphoma (MCL) is a heterogeneous and uncommon non-Hodgkin lymphoma that affects predominantly older patients and often is associated with an aggressive clinical […]
The Use of Chimeric Antigen Receptor T Cells in Patients With Non-Hodgkin Lymphoma
Abstract: Resistance to conventional lines of therapy develops in approximately 20% of all patients with lymphoma. These patients have a dismal prognosis, with an expected […]